Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
1045 Sansome St, Suite 321, San Francisco, CA
hello@withpower.com(415) 900-4227
About UsClinical Trials by ConditionAll Clinical TrialsWork With Us
1
Directories
Conditions
Cities
States
Popular Categories
Depression & Anxiety
Neurology
Psychiatry
Pain
Metabolism
Treatments
Locations
Florida
New Jersey
North Carolina
Texas
Ohio
California
Pennsylvania
Kentucky
New York
Indiana
Psychology Related
Depression
Schizophrenia
Anxiety
PTSD
ADHD
Autism
Bipolar Disorder
Addiction
OCD
Eating Disorder
Treatments
Psilocybin
IVF
Dental Implant
Weight Loss
Smoking
Platelet-Rich Plasma
Testosterone
Saxenda
Melatonin
Entresto
Cities
Saint Louis
Columbus
Portland
Ann Arbor
Aurora
Salt Lake City
Rochester
Birmingham
Detroit
New Haven
Terms of Service·Privacy Policy·Cookies
Cookies & Data Use Policy

At Power, we believe in using data responsibly to help you find the right clinical trials — without compromising your privacy. This page explains how we use cookies and personal data across www.withpower.com.

Before You Create a Profile

When you browse Power's website, you're opting in to our use of cookies. Cookies are used to improve your experience and help us understand how the site is used so that we can make improvements for you in the future. Specifically, we use cookies to:

Personalize Your Experience

We use cookies to customize your visit based on basic information like your general location (determined by your IP address). This allows us to:

  • Show you clinical trials that are geographically relevant to you
  • Tailor search results to match the conditions or keywords you've explored before
  • Pre-fill certain fields or remember your previous searches, so you don't have to repeat them

Save Your Preferences

We remember what you interact with during your visit — for example:

  • The conditions you search for
  • Whether you prefer certain types of studies (e.g., paid trials, trials for a specific age group)
  • Your sorting or filtering preferences when browsing trials

This helps us make your experience more efficient and personalized the next time you visit.

Understand How the Site Is Used

Cookies help us collect anonymous usage data so we can make Power better. We use these insights to:

  • Monitor how users move through the site — for example, which pages get the most traffic and where users tend to exit
  • Track how long visitors stay on each page and whether they find what they’re looking for
  • Identify points of friction or confusion so we can improve usability
  • Test design changes (like different page layouts or buttons) and measure which version performs better
  • Detect and fix bugs or slow-loading pages to maintain site reliability

These analytics are aggregated and do not include personal identifiers. We use tools like Google Analytics to process this data, but we don't use it to target ads or sell your information.

We do not:

  • Sell or share your personal data with advertisers
  • Use your behavior on our site to target you with third-party ads

All cookie use is designed to support your experience on Power — never to track you across the internet or monetize your information.

After You Create a Profile

When you sign up for a Power account, you agree to our Privacy Policy and Terms of Service. Creating a profile allows us to better serve you by tailoring the platform to your specific needs.

Once you create a profile:

  • We may collect additional information about your health and clinical interests to help us match you to the most relevant studies.
  • We continue to use cookies to remember your session, keep you logged in, and personalize your dashboard.
  • You have full control — you can delete your profile at any time, and we'll remove your personal data in accordance with our privacy practices.

We use your data solely to fulfill our mission: helping you find clinical trials that could be a fit — not for advertising or resale.

·Security
Condition
Suggested Conditions
  • Anxiety
  • Depression
  • Alzheimer's Disease
  • Weight Loss
  • Heart Disease
  • Cancer
  • Asthma
Location

    Scleroderma

    Current Location

    Search Clinical Trials
    Conditions
    Suggestions
    • Anxiety
    • Depression
    • Alzheimer's Disease
    • Weight Loss
    • Heart Disease
    • Cancer
    • Asthma
    Locations
    Suggestions
      Treatment Type
      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Trial Phase

      Trial Status

      Paid Participation

      Filters

      0

      Suggestions
      • Cognitive Behavioral Therapy
      • Medication Management
      • Group Therapy
      • Psychotherapy
      • Mindfulness-Based Therapy
      • Exposure Therapy

      Paid Participation

      Trial Status

      Trial Phase

      Clear All
      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

      41 Scleroderma Trials Near You

      Power is an online platform that helps thousands of Scleroderma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

      Learn More About Power
      No Placebo
      Highly Paid
      Stay on Current Meds
      Pivotal Trials (Near Approval)
      Breakthrough Medication

      Rapcabtagene Autoleucel for Systemic Sclerosis

      Columbus, Ohio
      The purpose of this study is to evaluate the efficacy, safety and tolerability of rapcabtagene autoleucel (administered once following lymphodepletion) in participants with severe refractory diffuse cutaneous systemic sclerosis relative to rituximab.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:18 - 65

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Renal Pathology, Hypertension, Others

      86 Participants Needed

      Nivolumab for Cancer

      Columbus, Ohio
      This phase Ib trial studies the side effects of nivolumab and to see how well it works in treating patients with autoimmune disorders and cancer that has spread to other places in the body or cannot removed by surgery. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Chemotherapy, Radiotherapy, Allogeneic Transplant, Others
      Must Not Be Taking:Anticancer Investigational Agents

      300 Participants Needed

      HZN-825 for Systemic Sclerosis

      Columbus, Ohio
      This is a randomized, double-blind, placebo-controlled, repeat-dose, multicenter trial. Participants will be screened within 6 weeks prior to the Baseline (Day 1) Visit. Approximately 300 participants who meet the trial eligibility criteria will be randomized on Day 1 in a 1:1:1 ratio to receive HZN-825 300 mg QD, HZN-825 300 mg BID or placebo for 52 weeks. The trial will include up to a 42-day Screening Period and a 52-week Double-blind Treatment Period. Participants will take their first dose of trial drug at the clinic and will participate in trial visits at Week 4 and every 6 weeks thereafter until Week 52. All participants who complete the Double-blind Treatment Period (Week 52) will be eligible to enter a 52-week extension trial (HZNP-HZN-825-302, NCT05626751). Participants not entering the extension trial will participate in a Safety Follow-up Visit 4 weeks after the last dose of trial drug.

      Trial Details

      Trial Status:Active Not Recruiting

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      301 Participants Needed

      SYNCAR-001 + STK-009 for Lupus

      Columbus, Ohio
      This is a phase 1 study of SYNCAR-001 + STK-009 in patients with severe, refractory systemic autoimmune rheumatic disease.
      No Placebo Group

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:CNS Manifestations, Gene Therapy, Dialysis, Others

      48 Participants Needed

      BMS-986278 for Pulmonary Fibrosis

      Columbus, Ohio
      The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3
      Age:21+

      Key Eligibility Criteria

      Disqualifiers:Idiopathic Pulmonary Fibrosis, Stroke, Heart Failure, Current Malignancy, Others
      Must Not Be Taking:Systemic Corticosteroids

      1092 Participants Needed

      CC-97540 for Severe Refractory Lupus

      Columbus, Ohio
      This trial is testing a new drug called CC-97540. It aims to help people with severe autoimmune diseases that don't get better with regular treatments. Researchers want to see if the drug is safe, how it moves through the body, and if it can improve patients' health.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Drug-induced SLE, Multiple Sclerosis, Psoriasis, Others

      270 Participants Needed

      Anifrolumab for Systemic Sclerosis

      Cincinnati, Ohio
      This trial is testing anifrolumab, an injectable medication, in adults with systemic sclerosis. The goal is to see if it can reduce immune system attacks to lessen symptoms and prevent further damage. Anifrolumab is a human monoclonal antibody that targets the type I interferon receptor and has been tested in multiple studies for systemic lupus erythematosus (SLE) and other autoimmune diseases.
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 3

      Key Eligibility Criteria

      Disqualifiers:Severe Cardiopulmonary, Overlap Syndromes, Malignancy, Others

      306 Participants Needed

      BI 685509 for Systemic Sclerosis

      Cincinnati, Ohio
      This trial is testing a medicine called Avenciguat to see if it helps adults with a condition called scleroderma, which affects the skin and internal organs. Participants take the medicine for several months. The study checks if the medicine improves lung function and other symptoms.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Pulmonary Disease, Others

      214 Participants Needed

      Belimumab for Systemic Sclerosis Interstitial Lung Disease

      Cincinnati, Ohio
      This study investigates the efficacy and safety of belimumab compared to placebo, in addition to standard therapy, for the treatment of participants with systemic sclerosis associated interstitial lung disease (SSc-ILD). The study will evaluate the effect of belimumab treatment on lung function as well as on extra-pulmonary disease manifestations, including skin thickening and general symptoms, such as fatigue, that impact quality of life (QoL).
      Prior Safety Data
      Pivotal Trial (Near Approval)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2, 3

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, SSc Renal Crisis, Others
      Must Be Taking:Mycophenolate, Methotrexate, Azathioprine

      300 Participants Needed

      PRA023 for Systemic Sclerosis-Associated ILD

      Toledo, Ohio
      This trial tests a new medication called tulisokibart on people with a lung disease called SSc-ILD. The goal is to see if it is safe and helps improve their condition.

      Trial Details

      Trial Status:Active Not Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Infections, Smoking, Others
      Must Be Taking:Nintedanib, MMF, Methotrexate, Azathioprine

      154 Participants Needed

      Amlitelimab + BI 1015550 for Scleroderma

      Cleveland, Ohio
      The goal of this clinical trial is to test efficacy of different investigational products (IPs) compared with placebo on the change from baseline to the end of the treatment period at Week 52 in lung capacity in participants with Interstitial Lung Disease Secondary to Systemic Sclerosis.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Abnormalities, Infected Ulcers, Renal Crisis, Others
      Must Not Be Taking:Rituximab, Tocilizumab, Nintedanib, Others

      400 Participants Needed

      Efzofitimod for Scleroderma-Related Lung Disease

      Cleveland, Ohio
      This trial is testing a new drug called efzofitimod to see if it can help people with a lung disease linked to systemic sclerosis. The goal is to find out if the drug can improve their breathing and skin health.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Heavy Smoker, Others
      Must Be Taking:Mycophenolate, Immunosuppressants

      25 Participants Needed

      FT819 for Lupus

      Cleveland, Ohio
      This is a phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and anti-B-cell activity of FT819 following treatment with or without auxiliary medicinal product (AMP) in participants with moderate to severe active systemic lupus erythematosus (SLE), antineutrophilic cytoplasmic antibody (ANCA)-associated vasculitis (AAV), idiopathic inflammatory myositis (IIM), and systemic sclerosis (SSc). The study will consist of a dose-escalation stage, followed by an expansion stage to further evaluate the safety and activity of FT819.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:12 - 70

      Key Eligibility Criteria

      Disqualifiers:Neurological Symptoms, Irreversible Organ Damage, Others
      Must Not Be Taking:CNS Medications

      244 Participants Needed

      Ianalumab for Systemic Sclerosis

      Ann Arbor, Michigan
      The purpose of this study is to evaluate efficacy, safety and tolerability of s.c. ianalumab administered in participants with diffuse cutaneous systemic sclerosis relative to placebo

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Rheumatic Disease, Pulmonary Disease, Others
      Must Not Be Taking:Cyclophosphamide, Biologics, Anti-fibrotics, Others

      200 Participants Needed

      CABA-201 for Scleroderma

      Ann Arbor, Michigan
      RESET-SSc: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T cell therapy, in Subjects with Systemic Sclerosis
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Severe Infections, Organ Transplant, Others

      12 Participants Needed

      Brain Boost Program for Scleroderma

      Ann Arbor, Michigan
      The purpose of this study is to examine whether an 8-week online educational group-based program tailored to people with systemic sclerosis can help improve cognitive function and well-being. The study team hypothesize that participants that receive the intervention will have better improvements immediately after treatment at week 8 in all cognitive function measures, non-cognitive symptoms, and self-management compared to those in the waitlist control.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Dementia, Head Injury, Neurological Disorders, Major Psychiatric Disorder, Others

      66 Participants Needed

      AI Health Coach for Scleroderma

      Ann Arbor, Michigan
      The purpose of this pilot study is to explore the use of a large language model (LLM) in providing education and behavioral health coaching for individuals with Systemic Sclerosis (SSc). The goal of the LLM is to help user set or modify behavioral goals, provide education, or emotional support as needed by the participant. The primary outcome for this study is to assess the feasibility and acceptability of using an AI-supported health coaching tool over a four-week period.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:No Internet, Non-English, New Treatments, Others

      20 Participants Needed

      Tibulizumab for Scleroderma

      Ann Arbor, Michigan
      The study is a Phase 2, multi-center, randomized, double-blind, placebo-controlled study to evaluate the effects of tibulizumab over 24 weeks (Period 1) in adult participants with systemic sclerosis, followed by an open-label extension period where all active participants will receive tibulizumab and will be evaluated for an additional 28 weeks (Period 2)

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Left Ventricular Failure, Pulmonary Hypertension, Renal Crisis, Others

      80 Participants Needed

      TENS for Scleroderma

      Ann Arbor, Michigan
      The goal of this pilot study is to assess the acceptability of the transcutaneous electrical acustimulation (TEA) device in treating Scleroderma-related gastroparesis. The main objective is: To evaluate the acceptability of TEA as an intervention for alleviating symptoms of distension and bloating in individuals diagnosed with Scleroderma. Participants will be provided with the TEA devices that will be applied to the skin for a total of 45 minutes twice daily after meals. Participants will be asked to fill out both daily diaries and biweekly questionnaires to assess for improvement in the gastroparesis symptoms. Participants will also be asked to complete the daily diaries in addition weekly questionnaires during a 4 week post-treatment follow-up period.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Pregnancy, Major Surgery, Diabetes, Others
      Must Be Taking:Prokinetics

      16 Participants Needed

      HZN-825 for Scleroderma

      Ann Arbor, Michigan
      This trial tests HZN-825, a medication, in people with diffuse cutaneous systemic sclerosis. It aims to see if the drug can improve lung function and overall health by affecting the disease process.
      No Placebo Group

      Trial Details

      Trial Status:Enrolling By Invitation

      Key Eligibility Criteria

      Disqualifiers:Not Listed

      240 Participants Needed

      Why Other Patients Applied

      "I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

      WR
      Obesity PatientAge: 58

      "I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

      ZS
      Depression PatientAge: 51

      "As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

      IZ
      Healthy Volunteer PatientAge: 38

      "I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

      AG
      Paralysis PatientAge: 50

      "I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."

      FF
      ADHD PatientAge: 31
      Match to a Scleroderma Trial

      Efgartigimod for Scleroderma

      Ann Arbor, Michigan
      The main purpose of this study is to evaluate the effect and safety of efgartigimod PH20 SC compared to placebo in adults with systemic sclerosis. The study consists of a screening period, a treatment period of up to 48 weeks and a safety follow-up period. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either efgartigimod PH20 SC or placebo. The total study duration can be up to approximately 15 months.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Digital Vasculopathy, Scleroderma Mimics, Others

      81 Participants Needed

      NKX019 for Systemic Sclerosis

      Ann Arbor, Michigan
      This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1, 2

      Key Eligibility Criteria

      Disqualifiers:Renal Failure, Liver Disease, Major Cardiac, Others

      144 Participants Needed

      Sodium Thiosulfate for Calcinosis

      Pittsburgh, Pennsylvania
      The specific objective of this study is to perform a small, open-label study to assess the safety and efficacy of intralesional, subcutaneous injection of STS on calcinosis symptoms and lesion size in systemic sclerosis (SSc), mixed connective tissue disease (MCTD) and dermatomyositis (DM) patients. Injection will be guided by ultrasound, lesion size assessed by ultrasound, and symptom burden by patient-reported outcome measures.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pregnancy

      20 Participants Needed

      Apollo Device for Scleroderma

      Pittsburgh, Pennsylvania
      The purpose of this study it to test the efficacy of a wearable device to improve symptom management and maximize qualify of life in systemic Sclerosis (SSc) patients in a randomized trial. Specifically, we will evaluate if the Apollo Neuro device may improve the two specific symptoms highest ranked by patients as affecting qualify of life (fatigue, Raynaud phenomenon) as co-primary outcomes.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Diabetes, Active Malignancy, Others
      Must Be Taking:Immunosuppressives, Vasodilators

      160 Participants Needed

      Stem Cell Transplant for Scleroderma

      Pittsburgh, Pennsylvania
      The purpose of this study is to determine whether a regimen of high-dose immunoablative therapy will demonstrate safety that is consistent or improved with other published regimens in SSc patients, while maintaining a treatment effect.
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2
      Age:8 - 60

      Key Eligibility Criteria

      Disqualifiers:Severe Cardiac, Pulmonary, Renal, Others
      Must Be Taking:DMARDS

      8 Participants Needed

      Brentuximab Vedotin for Systemic Sclerosis

      London, Ontario
      The purpose of this study is to assess safety and efficacy of Brentuximab vedotin, a CD30-directed antibody-drug conjugate, in patients with active diffuse cutaneous systemic sclerosis (dcSSc) who relapsed after discontinuation of Brentuximab vedotin.
      No Placebo Group
      Prior Safety Data

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Pulmonary Hypertension, Cardiac Disease, HIV, Others
      Must Be Taking:Brentuximab Vedotin

      11 Participants Needed

      Extracorporeal Photopheresis for Systemic Sclerosis

      London, Ontario
      This trial is testing a treatment called Extracorporeal Photopheresis for patients with a severe form of scleroderma. The treatment involves taking blood out, treating it with light and a drug, and then putting it back in. The goal is to see if this can safely reduce skin thickening and improve symptoms. Extracorporeal photopheresis (ECP) has been used for over 30 years, initially for cutaneous T-cell lymphoma and later for other diseases including scleroderma.
      No Placebo Group

      Trial Details

      Trial Status:Not Yet Recruiting
      Trial Phase:Phase 2

      Key Eligibility Criteria

      Disqualifiers:Cardiac Disease, Cancer, HIV, Others
      Must Not Be Taking:Photosensitizing Drugs, Immunosuppressants

      15 Participants Needed

      Diosmin for Digital Ulcers

      London, Ontario
      This study is performed to consider the safety and healing ability of diosmin in patients with systemic sclerosis (scleroderma) and open sores on their fingers (digital ulcers). Two (2) out of three (3) participants will receive active product. The participants will have four (4) visits over eight (8) weeks. Physical exams and photos will be performed. A variety of questions will be asked describing level of pain and lifestyle changes.

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Unphased

      Key Eligibility Criteria

      Disqualifiers:Infection, Cancer, Pregnancy, Others

      45 Participants Needed

      CNTY-101 for Lupus

      Chicago, Illinois
      CALiPSO-1 is a Phase 1, multi-centre, dose-confirmation study to evaluate the safety and efficacy of CNTY-101 in participants with refractory B cell-mediated autoimmune diseases including those with moderate to severe systemic lupus erythematosus (SLE) with or without lupus nephritis (LN), idiopathic inflammatory myopathies (IIM), and diffuse cutaneous systemic sclerosis (DcSSc).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1
      Age:17+

      Key Eligibility Criteria

      Disqualifiers:Hemodialysis, CNS Disease, Transplant, Others

      48 Participants Needed

      CTX112 for Lupus

      Chicago, Illinois
      This is a single-arm, open-label, multicenter, ascending dose Phase 1 study evaluating the safety and preliminary efficacy of CTX112 in adult subjects with refractory autoimmune diseases, including active systemic lupus erythematosus (SLE), systemic sclerosis (SSc), or idiopathic inflammatory myopathy (IIM).
      No Placebo Group

      Trial Details

      Trial Status:Recruiting
      Trial Phase:Phase 1

      Key Eligibility Criteria

      Disqualifiers:Organ Transplant, CNS Involvement, Malignancy, Others
      Must Not Be Taking:Anti-CD19 Therapy

      80 Participants Needed

      12

      Know someone looking for new options?
      Spread the word

      Why We Started Power

      We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

      Bask
      Bask GillCEO at Power
      Learn More About Trials
      How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?
      Match to a Trial
      Match to a Trial
      Search
      Scleroderma
      Show Map
      Map View
      Your Location

      Frequently Asked Questions

      How much do Scleroderma clinical trials pay?

      Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

      How do Scleroderma clinical trials work?

      After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across Scleroderma trials 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length for Scleroderma is 12 months.

      How do I participate in a study as a "healthy volunteer"?

      Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

      What does the "phase" of a clinical trial mean?

      The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

      Do I need to be insured to participate in a Scleroderma medical study?

      Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

      What are the newest Scleroderma clinical trials?

      Most recently, we added Stem Cell Transplant for Autoimmune Diseases, BMS-986515 for Autoimmune Diseases and ALLO-329 for Lupus to the Power online platform.

      Is there hope for scleroderma?

      Yes—although scleroderma still has no one-shot cure, survival and quality of life have improved dramatically thanks to earlier organ screening, targeted drugs that slow lung and skin damage, and even stem-cell transplants for the most aggressive cases. Prognosis varies by subtype, but many people—especially with limited disease—now live full lifespans when they partner with a rheumatology team, stay vigilant for lung or heart changes, and tap into clinical trials and support resources. In short, progress is real and ongoing, so there truly is hope.

      What is the best hospital in the US for scleroderma?

      No agency publishes an official “#1 hospital” for scleroderma, so experts judge centers by patient volume, multidisciplinary specialists, active clinical trials, and research output. Programs that consistently meet those benchmarks include Johns Hopkins (MD), University of Pittsburgh Medical Center (PA), Hospital for Special Surgery/Columbia (NY), Stanford (CA), Mayo Clinic (MN), Cleveland Clinic (OH), and Brigham and Women’s (MA). Ask any prospective center about how many scleroderma patients it sees each year, what organ-specific teams and trials are available, and whether telehealth or second-opinion services fit your insurance and travel limits.

      What triggers scleroderma?

      Scleroderma starts when a person who already carries several “risk” genes experiences an additional hit—most convincingly long-term exposure to silica dust or strong organic solvents, certain chemotherapy drugs (e.g., bleomycin), or, in a minority, an immune reaction linked to a recent cancer or infection. These triggers injure the small blood-vessel lining, the immune system over-reacts, and excess collagen is laid down, thickening skin and sometimes organs; however, in many patients no definite trigger is ever found, which is why avoiding heavy chemical exposure and staying up-to-date with routine health checks is wise but cannot fully prevent the disease.

      What would you not recommend for a patient with scleroderma?

      Think “anything that injures fragile skin, clamps down blood flow, or stresses the kidneys”—those are the main things to avoid in scleroderma. That means skipping tattoos or piercings; quitting smoking, vaping, or other nicotine; keeping fingers warm and steering clear of cold aisles or ice water; and avoiding medicines that tighten blood vessels (certain decongestants, non-selective beta-blockers, migraine ergot/triptan drugs) or high-dose steroids and other kidney-toxic drugs unless your specialist says otherwise. Review every new procedure or medication with your rheumatologist so safer substitutes or protections can be arranged.

      How much does it cost to treat scleroderma?

      Treating scleroderma can run anywhere from about US $10–25 k per year for milder cases that need mainly clinic visits, routine tests and inexpensive medicines, to well over US $50 k—and sometimes above US $100 k—when lung or heart complications require drugs like nintedanib, bosentan or prostacyclin infusions, frequent hospital stays, or stem-cell transplant. The number you personally face depends far more on disease severity and insurance coverage than on any single “sticker price,” so the smartest move is to have your care team outline the expected treatments up front and, at the same time, apply for insurer pre-authorisation and drug-company or charity copay programs that can slash out-of-pocket costs.

      Is scleroderma worse than rheumatoid arthritis?

      It depends on what you mean by “worse.” Systemic scleroderma is rarer but more life-threatening because it can scar internal organs; even with modern care, about 15–30 % of patients die within 10 years. Rheumatoid arthritis is less deadly but far more common and can severely damage joints and raise heart-disease risk if untreated. In short, scleroderma carries the higher risk of early death, while rheumatoid arthritis more often causes long-term disability—early diagnosis and aggressive treatment are crucial for both.

      What is a good supplement for scleroderma?

      Start by correcting any lab-proven deficiencies—vitamin D is low in many people with scleroderma, so your doctor may suggest 800–2,000 IU (or the dose needed to reach normal blood levels). After that, the best-studied add-ons are marine fish-oil (about 1–3 g EPA + DHA daily) and N-acetyl-cysteine, which small studies suggest can ease Raynaud’s attacks and digital ulcers; high-dose iron or vitamin A should be avoided unless you are clearly deficient. Always clear supplements with your rheumatologist or pharmacist, as kidney, lung, or esophageal involvement—and the drugs used to treat them—can change what is safe for you.

      What are the new treatments for scleroderma?

      Two medicines are now FDA-approved to slow lung damage in systemic sclerosis: nintedanib (approved 2019) and tocilizumab (approved 2021). Beyond these, several therapies are showing benefit in late-stage studies—B-cell depletion with rituximab, T-cell modulation with abatacept, JAK inhibitors, cannabinoid-mimetic lenabasum, and autologous stem-cell transplant—so a rheumatologist may discuss clinical-trial or specialty-center referral if standard drugs are not enough.

      How debilitating is scleroderma?

      Scleroderma ranges from localized skin thickening that is more of a nuisance to a systemic form that can stiffen joints, cause painful Raynaud’s attacks, and—if it scars the lungs, heart or kidneys—significantly cut stamina or even shorten life; fortunately, only a subset of patients develop these severe complications. Thanks to earlier diagnosis, blood-pressure drugs that prevent kidney crisis, medications that slow lung scarring, and physical/occupational therapy, most people now remain independent and 10-year survival is roughly 75–85 %, so close monitoring with a rheumatologist is key to limiting how debilitating the disease becomes.

      Does walking help scleroderma?

      Yes—done correctly, regular walking can help many people with scleroderma by improving blood flow to the fingers and toes, keeping joints and skin less stiff, and boosting heart-lung fitness and energy levels; small studies even show gains in grip strength and walking distance after supervised programs. Start with short, comfortable walks (5-10 minutes) on level ground, dress warmly to protect against Raynaud’s, use well-fitting shoes if you have foot ulcers, and have your doctor or physiotherapist adjust the plan if you have lung involvement or pulmonary hypertension. Think of walking as one part of an overall movement routine—aim for about 150 minutes a week of gentle activity, adding stretching or hand exercises—as tolerated and monitored by your care team.

      Popular Searches

      By Condition

      Depression Clinical Trials

      Anxiety Clinical Trials

      Schizophrenia Clinical Trials

      ADHD Clinical Trials

      Bipolar Disorder Clinical Trials

      Multiple Sclerosis Clinical Trials

      Autism Clinical Trials

      Treatment Resistant Depression Clinical Trials

      Borderline Personality Disorder Clinical Trials

      Social Anxiety Disorder Clinical Trials

      Parkinson's Disease Clinical Trials

      Alzheimer's Disease Clinical Trials

      By Location

      Clinical Trials in California

      Clinical Trials in Florida

      Clinical Trials in Texas

      Clinical Trials in New York

      Clinical Trials in Ohio

      Clinical Trials in Illinois

      Clinical Trials in Pennsylvania

      Clinical Trials in Michigan

      Clinical Trials in North Carolina

      Clinical Trials in Massachusetts

      Clinical Trials in Missouri

      Clinical Trials in Minnesota

      Other People Viewed

      By Subject

      Top Anxiety Clinical Trials

      Top Pediatric Asthma Clinical Trials

      Top Anal Cancer Clinical Trials

      Top Peritoneal Cancer Clinical Trials

      Top Gastroenterology Clinical Trials

      Top Cardiomyopathy Clinical Trials

      Top Anorexia Clinical Trials

      Top Neurofibromatosis Clinical Trials

      Top Hernia Clinical Trials

      Top Rosacea Clinical Trials

      Top Glaucoma Clinical Trials

      Top Cholangiocarcinoma Clinical Trials

      By Trial

      Electrocorticography for Brain Tumor

      Sucralose for Healthy Subjects

      27T51 Therapy for Ovarian Cancer

      Stereotactic Radiation for Breast Cancer

      Oral Ifetroban for Scleroderma

      CD19 CAR T-Cell Therapy for Scleroderma

      Rilzabrutinib for Immune Thrombocytopenia

      Ketone Supplement for Colorectal Cancer Prevention

      Fractional Laser + Tirbanibulin for Skin Cancer

      Stem Cell Transplant Prep Regimen for Immune Deficiency Disorders

      Bimodal Streaming for Hearing Loss

      GEN1042 for Advanced Cancers

      Related Searches

      Top Treatment for Carfilzomib Clinical Trials

      Top Clinical Trials near Fargo, ND

      Top Hnscc Clinical Trials

      Prehabilitation & Education for Breast Cancer

      Smartphone App for Cancer-Related Pain Management

      Audiovisual Stimulation for Hemianopia from Brain Tumors

      Infigratinib for Achondroplasia

      Hyaluronic Acid Filler for Jaw Contouring

      Exercise for Preterm Birth

      CerebroFlo™ EVD Catheter for Intraventricular Hemorrhage

      Insul-In This Together Program for Type 1 Diabetes

      Online Health Support for Endometrial Cancer